A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose cytarabine (LDAC) might improve the outcomes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Swaminathan, Mahesh, Kantarjian, Hagop M., Levis, Mark, Guerra, Veronica, Borthakur, Gautam, Alvarado, Yesid, DiNardo, Courtney D., Kadia, Tapan, Garcia-Manero, Guillermo, Ohanian, Maro, Daver, Naval, Konopleva, Marina, Pemmaraju, Naveen, Ferrajol, Alessandra, Andreeff, Michael, Jain, Nitin, Estrov, Zeev, Jabbour, Elias J., Wierda, William G., Pierce, Sherry, Pinsoy, Maria Rhona, Xiao, Lianchun, Ravandi, Farhad, Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327731/
https://www.ncbi.nlm.nih.gov/pubmed/33853292
http://dx.doi.org/10.3324/haematol.2020.263392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327731/
https://www.ncbi.nlm.nih.gov/pubmed/33853292
http://dx.doi.org/10.3324/haematol.2020.263392

Ejemplares similares